Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03474822Phase 1Recruiting

Plasmodium Immunotherapy for Breast and Liver Cancers

Role: lead

NCT04165590Phase 1Recruiting

Plasmodium Immunotherapy for Advanced Malignant Solid Tumors

Role: lead

NCT03375983Phase 1Recruiting

Plasmodium Immunotherapy for Advanced Cancers

Role: lead

NCT02786589Phase 1Unknown

Plasmodium Immunotherapy for Lung Cancer

Role: collaborator

All 4 trials loaded